CN116836264A - Recombinant humanized fibronectin rhFEB and application thereof - Google Patents
Recombinant humanized fibronectin rhFEB and application thereof Download PDFInfo
- Publication number
- CN116836264A CN116836264A CN202310642873.1A CN202310642873A CN116836264A CN 116836264 A CN116836264 A CN 116836264A CN 202310642873 A CN202310642873 A CN 202310642873A CN 116836264 A CN116836264 A CN 116836264A
- Authority
- CN
- China
- Prior art keywords
- rhfeb
- fibronectin
- recombinant humanized
- cell
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010067306 Fibronectins Proteins 0.000 title claims abstract description 42
- 102000016359 Fibronectins Human genes 0.000 title claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 230000001737 promoting effect Effects 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 16
- 239000002537 cosmetic Substances 0.000 claims abstract description 8
- 230000032683 aging Effects 0.000 claims abstract description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 230000004927 fusion Effects 0.000 claims description 11
- 230000008439 repair process Effects 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000003259 recombinant expression Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- 239000012598 cell culture matrix Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 43
- 210000003491 skin Anatomy 0.000 abstract description 13
- 230000021164 cell adhesion Effects 0.000 abstract description 8
- 238000010353 genetic engineering Methods 0.000 abstract description 8
- 230000003712 anti-aging effect Effects 0.000 abstract description 7
- 230000014509 gene expression Effects 0.000 abstract description 6
- 108010035532 Collagen Proteins 0.000 abstract description 5
- 102000008186 Collagen Human genes 0.000 abstract description 5
- 229920001436 collagen Polymers 0.000 abstract description 5
- 102000037865 fusion proteins Human genes 0.000 abstract description 5
- 108020001507 fusion proteins Proteins 0.000 abstract description 5
- 238000000746 purification Methods 0.000 abstract description 5
- 238000004113 cell culture Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 210000004927 skin cell Anatomy 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 230000001153 anti-wrinkle effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 101100274957 Mus musculus Col1a1 gene Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101710137510 Saimiri transformation-associated protein Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the technical field of genetic engineering, and discloses recombinant humanized fibronectin rhFEB and application thereof. According to the invention, through analyzing, screening and combining different polypeptide substances, a functional motif of human III type collagen proliferation promoting function is sequentially inserted into the N end of a humanized fibronectin EDB fragment by utilizing a genetic engineering means, and the amino sequence of the polypeptide fusion protein rhFEB is shown as SEQ ID NO. 1. The recombinant humanized fibronectin rhFEB with anti-aging performance is obtained by carrying out expression purification in vitro by a genetic engineering method, and the rhFEB has higher cell restoration promoting capability, solubility and high absorptivity. The recombinant humanized fibronectin rhFEB has the functions of resisting aging, affecting cell adhesion, promoting micro-angiogenesis and repairing damaged skin cells, and can be used as a raw material in the fields of cosmetics, skin care products, cell culture matrixes and the like.
Description
Technical Field
The invention relates to the technical field of genetic engineering, in particular to recombinant humanized fibronectin rhFEB and application thereof.
Background
Anti-aging means inhibiting and delaying the aging process of the body. The skin and other organs gradually tend to age with the increasing age, and the anti-aging meaning is to slow down the steps of skin aging, so that the skin of a person is smoother and finer, and wrinkles are reduced.
The dermal extracellular matrix (ECM) plays a vital role in skin aging, and their damage is closely related to skin aging, and collagen loss directly leads to skin sagging, aging, and elasticity decrease. ECM proteins mainly include collagen, fibronectin, elastin, and laminin. Fibronectin (FN) has multiple functional domains, plays an important role in cell adhesion and migration, and can bind to heparin, integrin receptors, collagen and the like to initiate various intracellular signaling pathways, and can also maintain the stability of ECM. FN repeats 12 to 14 form a hybrid binding domain, called type II heparin binding domain, capable of interacting with most platelet derived growth factors. Type II heparin binding domains also play a critical role in cell adhesion by binding to cell surface heparan sulfate proteoglycans. The fibronectin "cell binding domain" FNIII10 (hereinafter FN 10) comprises the RGD sequence (Arg-Gly-Asp) and has sites for promoting cell attachment, and can bind to various integrins (such as alpha V beta 3, alpha V beta 5, alpha V beta 6, etc.) on the cell surface. Integrins are derived from stem cells of the blood, such as hematopoietic stem cells, and bone marrow stem cells express integrin beta 3 on their surface. Stem cells are located in an environment consisting of neighboring cells, ECM, autocrine and paracrine soluble growth factors, etc. Therefore, the research and development of a related peptide with excellent anti-aging effect is an important direction of anti-aging product research.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a recombinant humanized fibronectin rhFEB and application thereof.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
in a first aspect, the invention provides recombinant humanized fibronectin rhFEB, the amino sequence of which is shown as SEQ ID NO. 1.
The invention utilizes genetic engineering means to insert functional motifs of human type III collagen proliferation promotion into the N end of the humanized fibronectin EDB fragment in sequence to form a novel polypeptide fusion protein, and the novel polypeptide fusion protein is expressed and purified in vitro by a genetic engineering method to obtain the recombinant humanized fibronectin rhFEB with anti-aging performance, which has the characteristics of high permeability, high reparative property, high safety and the like. The recombinant humanized fibronectin rhFEB has the functions of resisting aging, affecting cell adhesion, promoting micro-angiogenesis and repairing damaged skin cells, and has wide application prospects in skin care products and cosmetics.
In a second aspect, the present invention provides a gene encoding said recombinant humanized fibronectin rhFEB.
As a preferred embodiment of the gene of the present invention, the nucleotide sequence is shown in SEQ ID NO. 2.
In a third aspect, the invention provides a fusion polypeptide comprising the recombinant humanized fibronectin rhFEB.
As a preferred embodiment of the fusion polypeptide according to the invention, at least one His-tag at the N-and/or C-terminus of the recombinant humanized fibronectin rhFEB is further comprised.
As a further preferred embodiment of the fusion polypeptide according to the invention, the amino sequence is shown in SEQ ID NO. 3.
As a further preferred embodiment of the fusion polypeptide of the present invention, the nucleotide coding sequence is shown in SEQ ID NO. 4.
In a fourth aspect, the present invention provides a recombinant expression vector comprising the above gene. Preferably, the expression vector is pET-20b.
In a fifth aspect, the present invention provides a recombinant bacterium comprising the recombinant expression vector described above. Preferably, the host cell of the recombinant bacterium is BL21.
In a sixth aspect, the present invention uses the recombinant humanized fibronectin rhFEB, the gene, and the fusion polypeptide in the preparation of any one of a to d:
a. cosmetic or skin care products for cell anti-photoaging;
b. cosmetic or skin care products for promoting cell repair;
c. cell culture matrix for promoting cell repair;
d. an anti-skin aging and repair agent; preferably, the formulation is a cosmetic or skin care product.
Compared with the prior art, the invention has the beneficial effects that:
according to the invention, different polypeptide substances are analyzed, screened and combined, and a functional motif of human III type collagen proliferation promoting function is sequentially inserted into the N end of the humanized fibronectin EDB fragment by utilizing a genetic engineering means, so that a polypeptide fusion protein rhFEB is obtained. The recombinant humanized fibronectin rhFEB with anti-aging performance is obtained by carrying out expression purification in vitro by a genetic engineering method, and the rhFEB has higher cell restoration promoting capability, solubility and high absorptivity. The recombinant humanized fibronectin rhFEB has the functions of resisting aging, affecting cell adhesion, promoting micro-angiogenesis and repairing damaged skin cells, and can be used as a raw material in the fields of cosmetics, skin care products, cell culture matrixes and the like.
Drawings
FIG. 1 is a construction map of E.coli recombinant expression plasmid pET20b-rhFEB used in the examples of the present invention.
FIG. 2 is an agarose gel electrophoresis of an amplified fragment of the nucleic acid DNA sequence of fibronectin rhFEB of the invention. In the figure, "M" refers to agarose gel electrophoresis marker, "-" refers to negative control, "+" refers to amplification of the fragment of interest, about 1860bp.
FIG. 3 is a diagram of the protein strain-induced polyacrylamide gel electrophoresis of rhFEB of the present invention. In the figure, "M" refers to polyacrylamide gel electrophoresis marker, "1" refers to a sample of a strain before induction, and "2" refers to a sample of a strain production protein after induction.
FIG. 4 shows the results of Western blotting experiments on the rhFEB protein of the present invention. In the figure, "M" refers to a polyacrylamide gel electrophoresis marker, and "1" refers to a sample of a target protein.
FIGS. 5 and 6 show the results of the Hacat cell adhesion assay of rhFEB of the present invention. The rhFEB has obvious effect on the adhesion promotion capability of cells and has similar adhesion promotion effect with EGF.
FIGS. 7 and 8 show the results of cell scratch repair activity detection of rhFEB of the present invention. Figure 7 shows cell streaking experiments 24h and 48h after dosing. The results show that the cell scratch repair activity of the rhFEB has obvious repair effect on the control group and is similar to the EGF effect.
FIGS. 9 and 10 show the results of experiments on the effects of rhFEB of the present invention on HSF cell compaction and wrinkle resistance. The results show that the rhFEB has the effects of tightening and anti-wrinkle on cells.
FIG. 11 shows the inhibitory effect of rhFEB of the present invention on elastase.
FIG. 12 shows qpcr results of rhFEB of the present invention for conversion of macrophage phenotype to M1.
FIG. 13 is a rhFEB-induced ECV304 cell lumen formation of the present invention.
FIG. 14 shows wound recovery at various times after administration of db/db mice.
FIG. 15 shows the wound healing rate of db/db mice.
FIG. 16 shows HE staining of wound tissue after 29d dosing of db/db mice. The results showed that rhFEB follicle formation was best seen in the administered group with no significant difference in epidermis thickness.
Detailed Description
For a better description of the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the following specific examples. It will be appreciated by persons skilled in the art that the specific embodiments described herein are for purposes of illustration only and are not intended to be limiting. Unless otherwise indicated, the terms used have the general technical meaning as understood by those skilled in the art.
The test methods used in the examples are conventional methods unless otherwise specified; the materials, reagents and the like used, unless otherwise specified, are all commercially available.
Example 1: expression and purification of recombinant humanized fibronectin rhFEB
(1) Construction and identification of pET20b-rhFEB recombinant plasmid
The amino acid sequence of the recombinant humanized fibronectin rhFEB is shown as SEQ ID NO. 1, and the encoding nucleotide sequence is shown as SEQ ID NO. 2.
The invention adopts an artificial method to construct pET20b-rhFEB recombinant plasmid. Nde I and Xho I cleavage sites (see SEQ ID NO: 4) were introduced at the 5 'and 3' ends of the coding nucleotide sequence, respectively. To facilitate subsequent purification, 6 histidine tags (see SEQ ID NO: 3) were added to each of the 5 'and 3' ends, which were ligated into the pET20b vector (available from Jin Weizhi company) by Nde I/Xho I double cleavage to give pET20b-rhFEB recombinant plasmid (see FIG. 1).
(2) Expression of rhFEB proteins
Transforming the gene expression vector pET20b-rhFEB into escherichia coli BL21, selecting positive clones in LB solid medium (containing 100 mug/mL ampicillin), inoculating the positive clones in LB liquid medium (containing 100 mug/mL ampicillin), culturing at 37 ℃ for 3-5 hours to OD 600 IPTG was added to a final concentration of 1mM at 0.5, and the culture was induced at 37℃for 4 hours, and the cells were collected by centrifugation.
(3) Purification of rhFEB proteins
The collected cells were added to PBS buffer at ph=7.4, crushed by using a homogenizer at 600bar, and centrifuged at high speed for 20 minutes, and the collected supernatant was purified by a nickel column (Ni Sepharose 6Fast Flow, available from GE) at a loading Flow rate of 0.7mL/min. And then balancing by using PBS buffer solution with pH=7.4, adopting imidazole gradient elution, collecting an outflow peak at 300mM, and desalting an eluted sample by G25 to obtain the high-purity protein. Purified rhFEB protein was obtained by SDS-PAGE protein gel and Western Blotting on the molecular weight and immunological verification of recombinant protein (as shown in FIGS. 2, 3 and 4).
Example 2: hacat cell adhesion experiments of fibronectin rhFEB.
Fibronectin rhFEB solution of example 1, 125. Mu. Mol/L EGF (EGF group) and blank aqueous control (Ctrl group) were added to 96-well plates at 50. Mu.l different protein concentrations per well and blow dried under sterile conditions. Hacat cell (human immortalized keratinocytes, purchased from ATCC) concentration was adjusted at 1.2X10 per well 4 Plating, incubating at 37 ℃, washing with PBS, adding 10 mu L of MTT and 5% CO into each hole after culturing for several hours 2 Culturing in incubator for 4 hr, sucking off culture solution, adding stop solution DMSO, and performing color comparison under enzyme label instrument (measuring absorbance at 570nm with 630nm as reference wavelength, and recording measurement result).
Fibronectin rhFEB cell adhesion experiments are shown in FIGS. 5 and 6: between 8nM and 2000nM, rhFEB has adhesion promoting effect on Hacat cells. At a concentration of 125. Mu. Mol/L, rhFEB has the best adhesion promoting effect on Hacat cells. The Ctrl group has small cell number, and the cells are round and are not spread; the EGF group and the rhFEB group have significantly increased cell adhesion numbers compared with the Ctrl group, and cells are in a spread state.
Example 3: hacat cell scratch assay of fibronectin rhFEB.
The marker pen was used to draw a horizontal line on the back of the 12-well plate before the plate was inoculated with cells (the same field of view was positioned for convenient photographing). After digestion, cells are inoculated into 12-well plates, the number of which is preferably the number of plates that are fully plated after adherence (when the number is small, the cells can be cultured for a period of time until the plates are fully plated, ensuring that the cells reach a density of 100% fusion). After the cells grow to the bottom of the plate, the 100 mu L gun head is perpendicular to the pore plate, and cell scratches are manufactured at the same positions along the scribing line of the back of the plate, so that the width of each scratch is consistent as much as possible. The cell culture solution was aspirated, the well plate was washed three times with PBS, and cell debris generated by scratches was washed off. A medium containing 1% serum and containing the rhFEB protein of example 1 (125 nM concentration) was added, and EGF, FN (recombinant expression at the pharmaceutical center, FN fragment in rhFEB protein), CC (a collagen-like protein, designed by COLA1, ID:79BC036531.2,2120-2164nt, synthesized by GL biochemistry) at the same molar concentration was used as a control group, and the record was photographed. And (3) placing the culture plate into an incubator to be cultured for 24 hours and 48 hours according to the concentration set by the result of the cell scratch experiment, and taking out and photographing. And according to the collected pictures, analyzing by using Image J software (National Institutes of Health) to obtain the scratch area, and finishing the data to obtain the experimental result.
Calculation of the percentage of wound healing (Wound Healing Percentage): the percentage of wound healing is obtained from the ratio of the area of the part that heals at a certain time (the area of the beginning-the area of the point in time) to the initial area, based on the area of the scratch that was the beginning. Namely:
the scratch test results are shown in fig. 7 and 8: after 48 hours of administration, compared with a blank group, the group to which the rhFEB protein is administered has the effect of promoting the healing of scratches, the chemically synthesized collagen fragment CC has no obvious promoting effect, the FN protein has the effect of promoting the healing of scratches, but the effect is poorer than that of the rhFEB protein, the rhFEB fusion protein has the synergistic effect, and the healing rate of the rhFEB group is similar to that of the EGF group. The rhFEB has high-efficiency repairing capability on skin wound surfaces.
Example 4: tightening and anti-wrinkle efficacy test experiment of fibronectin rhFEB
Experiments were performed according to the Shanghai daily chemical industry Association published body standard T/SHrh 031-2020, and the difference in expression of type I collagen after HSF cell administration was detected by WB. TGF beta 1 was purchased from ABclonal, cat: RP02514; type I collagen antibodies were purchased from CST, cat: 72026s.
The results are shown in fig. 9 and 10: the concentration of 2nM and 20nM of rhFEB promotes the secretion of type I collagen, and the rhFEB has the effects of tightening and anti-wrinkle.
Example 5: elastase inhibition assay
Preparation of a solution containing 400mmol/L NaCl and 10mmol/L CaCl 2 By mixing 10 mU L of rhFEB solution with different mass concentration and 90 mU L of 20mU L of elastase solution, incubating at 25 ℃ for 20min, adding 100 mU L of 2mmol/L of AAAPAN solution, measuring absorbance value at 405nm after 30min, and carrying out parallel measurement for 3 times by taking EGCG (epigallocatechin gallate, shanghai-derived leaf biotechnology Co., ltd.) as positive control.
The results are shown in FIG. 11: elastin is an important structural protein in skin composition, and is degraded during skin aging due to the increase in the content of matrix metalloproteinases such as elastase, resulting in loss of skin elasticity. The rhFEB has good inhibition effect on elastase, and can enhance the stretching resistance of skin, keep elasticity and tightness.
Example 6: macrophage-promoting phenotype switching assay
RAW264.7 cell plating with good growth state and normal cell morphology is selected according to 5×10 per well 5 The cells were inoculated into six-well plates, and after overnight adhesion, the induction reagents were added to each of the cells for 24 hours. Normal: H-DMEM complete medium containing 10% FBS without double antibody, M1 positive group: complete medium+100 ng/ml LPS+20ng/ml IFN-. Gamma.s; m2 positive group: complete medium+20 ng/ml IL-4; normal+rhfeb: normal+10 μg/ml rhFEB; m1+rhfeb: m1 medium+10 μg/ml rhFEB; m2+rhfeb: m2 medium+10. Mu.g/ml rhFEB. RNA was extracted after the induction was completed, and gene level of iNOS (M1 type marker) was detected.
The results are shown in FIG. 12: Q-PCR results show that rhFEB promotes the conversion of macrophages into M1 type, and shows that rhFEB can promote the release of pro-inflammatory cytokines by macrophages, activate other immune cells and initiate inflammatory reaction, and is a defending mode of an organism against external injury (such as UV light skin irritation injury).
Example 7: lumen formation promotion experiment
Matrigel gel, 200 μl gun box, 96-well plate were placed in a refrigerator at 4deg.C overnight pre-chilled. The jelly-like Matrigel is respectively mixed with rhFN solution and EGF protein solution according to the volume ratio of 50 mu L/hole (1:4) and paved into the hole of a precooled 96-well plate, meanwhile, a Control group is arranged to be that a serum-free RMPI.1640 culture medium is mixed with the Matrigel according to the volume ratio of 1:4, the Matrigel is stood for 2 hours in a refrigerator at the temperature of 4 ℃ to form a hillock shape, and after no bubbles are observed, the Matrigel is placed in a incubator at the temperature of 37 ℃ for 16 hours to solidify the Matrigel.
ECV304 cells were counted by digestion, diluted to a cell suspension with a cell density of 15 ten thousand cells/mL, and added dropwise to the surface of Matrigel gel, and incubated in a 37℃incubator with 100. Mu.L per well, two duplicate wells per group. Placing in a incubator at 37 ℃ for 12 hours, taking out, and taking a photograph by a fluorescence microscope.
The results are shown in FIG. 13: no formed tube ring exists in Ctrl group, and rhFEB promotes ECV304 tube ring formation, and the effect is consistent with EGF. The rhFEB of the present invention can promote the formation of micro-blood vessels.
Example 8: db/db mice wound healing observations
Diabetic db/db mice, 10 females, body weight 40±2g. On the day of the experiment, 3% pentobarbital sodium was intraperitoneally anesthetized, and the back depilatory cream was used for depilation with a depilation area of about 3cm×3cm. The animal takes the prone position under the anesthesia state, and the skin on the back is eliminatedToxin is arranged at the position below the scapula and beside the left and right sides of the spinal midline by about 2mm, a cornea trephine with the diameter of 10mm is used for manufacturing a whole-course skin defect wound surface reaching the fascia, and the wound surface area is 0.8cm 2 And a record was photographed. After the molding was completed, the wound surface was coated with the corresponding samples (concentration of rhFEB and aFGF: 200. Mu.g/g) at 0.1 g/g. After 24h of 28d dosing, the animals are scored and photographed correspondingly, the mice are sacrificed by the euthanasia operation, normal skin 3-4 mm away from the wound margin is sheared, wound tissues are cut completely deep to the myometrium, and the obtained slices are subjected to HE staining.
The results are shown in fig. 14, 15 and 16: the rhFEB group has better healing performance than the aFGF group, and in the section HE staining, the administration group has the best formation condition of rhFEB hair follicles, and the epidermis thickness among the groups has no obvious difference;
finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. The recombinant humanized fibronectin rhFEB is characterized in that the amino sequence of the recombinant humanized fibronectin rhFEB is shown as SEQ ID NO. 1.
2. A gene encoding the recombinant humanized fibronectin rhFEB of claim 1.
3. The gene according to claim 2, wherein the nucleotide sequence is shown in SEQ ID NO. 2.
4. A fusion polypeptide comprising the recombinant humanized fibronectin rhFEB of claim 1.
5. The fusion polypeptide of claim 4, further comprising at least one His tag at the N-terminus and/or C-terminus of the recombinant humanized fibronectin rhFEB.
6. The fusion polypeptide of claim 5, wherein the amino sequence is as shown in SEQ ID NO. 3.
7. The fusion polypeptide of claim 5, wherein the nucleotide coding sequence is set forth in SEQ ID NO. 4.
8. A recombinant expression vector comprising the gene of claim 2 or 3.
9. A recombinant bacterium comprising the recombinant expression vector of claim 8.
10. Use of the recombinant humanized fibronectin rhFEB of claim 1, the gene of claim 2 or 3, the fusion polypeptide of any one of claims 4 to 7 in the preparation of any one of products a to d:
a. cosmetic or skin care products for cell anti-photoaging;
b. cosmetic or skin care products for promoting cell repair;
c. cell culture matrix for promoting cell repair;
d. an anti-skin aging and repairing preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310642873.1A CN116836264B (en) | 2023-06-01 | 2023-06-01 | Recombinant humanized fibronectin rhFEB and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310642873.1A CN116836264B (en) | 2023-06-01 | 2023-06-01 | Recombinant humanized fibronectin rhFEB and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116836264A true CN116836264A (en) | 2023-10-03 |
| CN116836264B CN116836264B (en) | 2024-02-20 |
Family
ID=88169625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310642873.1A Active CN116836264B (en) | 2023-06-01 | 2023-06-01 | Recombinant humanized fibronectin rhFEB and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116836264B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117447580A (en) * | 2023-12-18 | 2024-01-26 | 朗肽生物制药股份有限公司 | Application of basic fibroblast growth factor reconstruction protein in skin care product |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002058485A (en) * | 2000-08-16 | 2002-02-26 | Terumo Corp | Osteogenesis-promoting fusion protein having collagen- binding property |
| CN103122027A (en) * | 2012-11-26 | 2013-05-29 | 杨霞 | Recombinant human collagen and production method thereof |
| CN109593126A (en) * | 2018-11-28 | 2019-04-09 | 山西锦波生物医药股份有限公司 | Polypeptide, its production method and purposes |
| CN112321723A (en) * | 2020-10-23 | 2021-02-05 | 广州暨南大学医药生物技术研究开发中心有限公司 | Polypeptide compound for resisting skin photoaging and application thereof |
| CN112955474A (en) * | 2018-07-17 | 2021-06-11 | 上海一宸医药科技有限公司 | Long-acting fibronectin type III domain fusion proteins |
| CN114920827A (en) * | 2022-06-29 | 2022-08-19 | 山西锦波生物医药股份有限公司 | Polypeptides and uses thereof |
-
2023
- 2023-06-01 CN CN202310642873.1A patent/CN116836264B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002058485A (en) * | 2000-08-16 | 2002-02-26 | Terumo Corp | Osteogenesis-promoting fusion protein having collagen- binding property |
| CN103122027A (en) * | 2012-11-26 | 2013-05-29 | 杨霞 | Recombinant human collagen and production method thereof |
| CN112955474A (en) * | 2018-07-17 | 2021-06-11 | 上海一宸医药科技有限公司 | Long-acting fibronectin type III domain fusion proteins |
| US20210300995A1 (en) * | 2018-07-17 | 2021-09-30 | Shanghai Yichen Biomed Co. Ltd | Long-acting fibronectin type III domain fusion protein |
| CN109593126A (en) * | 2018-11-28 | 2019-04-09 | 山西锦波生物医药股份有限公司 | Polypeptide, its production method and purposes |
| CN112321723A (en) * | 2020-10-23 | 2021-02-05 | 广州暨南大学医药生物技术研究开发中心有限公司 | Polypeptide compound for resisting skin photoaging and application thereof |
| CN114920827A (en) * | 2022-06-29 | 2022-08-19 | 山西锦波生物医药股份有限公司 | Polypeptides and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| DUDLEY H MCNITT: "Streptococcal Collagen-like Protein 1 Binds Wound Fibronectin: Implications in Pathogen Targeting", 《CURRENT MEDICINAL CHEMISTRY》, vol. 26, no. 11, pages 1933 - 1945 * |
| GENBANK: "Accession No.:WP_233759214.1, hypothetical protein [Flagellimonas sp. HMM57]", 《GENBANK》 * |
| XIN LUO: "Recombinant expression a novel fibronectin-collage fusion peptide modulating stem cell stemness via integrin β3", 《APPLIED MICROBIOLOGY BIOTECHNOLOGY 》, vol. 106, no. 9, pages 3765 - 3776, XP037854473, DOI: 10.1007/s00253-022-11965-4 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117447580A (en) * | 2023-12-18 | 2024-01-26 | 朗肽生物制药股份有限公司 | Application of basic fibroblast growth factor reconstruction protein in skin care product |
| CN117447580B (en) * | 2023-12-18 | 2024-04-30 | 朗肽生物制药股份有限公司 | Application of basic fibroblast growth factor reconstruction protein in skin care product |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116836264B (en) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alitalo et al. | Extracellular matrix proteins of human epidermal keratinocytes and feeder 3T3 cells. | |
| CN116836264B (en) | Recombinant humanized fibronectin rhFEB and application thereof | |
| Lucas et al. | Mapping the lectin-like activity of tumor necrosis factor | |
| US5091173A (en) | Hair growth composition | |
| Tucker et al. | Comparison of intra-and extracellular transforming growth factors from nontransformed and chemically transformed mouse embryo cells | |
| CA2349875A1 (en) | Dna encoding a growth factor specific for epithelial cells | |
| EP2275440B1 (en) | Growth factor-mimicking peptides and uses thereof | |
| CN107344959B (en) | Ultrashort peptide Purin-WH for promoting skin repair, and preparation method and application thereof | |
| CN112321723B (en) | Polypeptide compound for resisting skin photoaging and application thereof | |
| US10725043B2 (en) | Three-dimensional fibroblast aggregate and in vitro 3D skin dermis model comprising same | |
| KR20110032587A (en) | Fgf10-derived peptides and uses thereof | |
| CN113576956A (en) | Preparation method and application of yeast extract for resisting aging and removing wrinkles | |
| CN116535520A (en) | Extracellular matrix protein fusion protein and preparation method and application thereof | |
| CN103834664B (en) | Recombinant human epidermal growth factor EGF and preparation method thereof | |
| JPH02502825A (en) | Neutrophil activating factor | |
| CN116970071B (en) | Recombinant elastin with anti-aging activity and preparation method and application thereof | |
| US20220340868A1 (en) | Method for preparing skin-derived pluripotent precursor cells | |
| CN117069864A (en) | Recombinant fibronectin-collagen fusion protein with repair activity and preparation method and application thereof | |
| Hormia | Expression of factor VIII-related antigen and ulex lectin binding sites in endothelial cells during long-term culture | |
| US20080064641A1 (en) | Novel Peptide and Pharmaceutical Composition Containing Said Peptide | |
| CN116789855A (en) | Recombinant human transdermal elastin and expression strain thereof | |
| EP1282434B1 (en) | Method for cell adhesion and wound healing | |
| CN113736737B (en) | Primary glioma-related fibroblast culture method | |
| Moller et al. | An in vitro system for the study of tracheal epithelial cells | |
| CN107904251A (en) | The preparation of TAT hEGF fusion proteins and its application in invisible face pack |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |